Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

NCT06561087 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Premalignant Lesion

Interventions

DRUG: Nivolumab

Sponsor

M.D. Anderson Cancer Center